Amedeo Smart

Free Medical Literature Service

 

Amedeo

Hypertension
  Free Subscription

Articles published in
Eur J Pharmacol
    August 2026
  1. GUO X, Gao C, Li L, Li Y, et al
    MYNN regulates hypoxia-induced PASMCs proliferation and migration by modulating the PDLIM1/NF-kappaB axis.
    Eur J Pharmacol. 2026;1031:179204.
    >> Share

  2. YUAN A, Bai Y, Jiang Y, Si S, et al
    The role and mechanism of rosiglitazone in endothelial-to-mesenchymal transition in pulmonary hypertension.
    Eur J Pharmacol. 2026 Aug 21:179227. doi: 10.1016/j.ejphar.2026.179227.
    >> Share

    July 2026
  3. PAN M, Hao X, Jia YC, Yang YX, et al
    Carvedilol, an Antihypertensive Drug That Reduces Morbidity and Mortality in Heart Failure, Alleviates Ferroptotic Damage in Cardiomyocytes and Hepatocytes.
    Eur J Pharmacol. 2026 Jul 15:179142. doi: 10.1016/j.ejphar.2026.179142.
    >> Share

  4. LI S, Pan H, Wei L, Guo X, et al
    GDF11 regulates hypoxia-induced pulmonary endothelial cell pyroptosis through SOX2/NLRP3 axis.
    Eur J Pharmacol. 2026;1030:179112.
    >> Share

  5. GAO T, Li Q, Chen J, Li Q, et al
    Baicalin downregulates Thromboxane A(2) receptor via SIRT1/NRF2 and NLRP3 pathways to attenuate Cyclosporine A-induced hypertension.
    Eur J Pharmacol. 2026;1030:179105.
    >> Share

    June 2026
  6. ZEESHAN A, Malik A, Ali M, Qaisar MN, et al
    Fenchone and cinnamyl acetate attenuate L-NAME-induced hypertension via modulation of vascular dysfunction, oxidative stress, and renal injury: An integrated network pharmacology, molecular docking, and ADMET study.
    Eur J Pharmacol. 2026;1030:179019.
    >> Share

    May 2026
  7. LI Y, Song S, Lin Q, Jin H, et al
    Sulfonated peptide alleviates hypertensive renal injury via antioxidant, anti-inflammatory, and renal metabolomics.
    Eur J Pharmacol. 2026 May 22:179006. doi: 10.1016/j.ejphar.2026.179006.
    >> Share

    April 2026
  8. LU YY, Lin FJ, Chen YC, Chin CG, et al
    Bradykinin modulates endothelin-1-enhanced and monocrotaline-induced pulmonary arterial hypertension-associated arrhythmogenesis in rabbit right ventricular outflow tract via a nitric oxide-dependent pathway.
    Eur J Pharmacol. 2026;1024:178896.
    >> Share

  9. ZHANG S, Ju G, Zhang J, Dong F, et al
    Sodium Houttuyfonate Alleviates Monocrotaline-induced Pulmonary Hypertension by Regulating Canonical Transient Receptor Potential Channel Proteins via CHIP.
    Eur J Pharmacol. 2026 Apr 17:178874. doi: 10.1016/j.ejphar.2026.178874.
    >> Share

    March 2026
  10. ZHANG Z, Ma X, Su C, Meng J, et al
    Perfluorocarbon ameliorates high-altitude pulmonary edema and blood-gas barrier dysfunction in a canine model and a lung-on-chip model by suppressing the HIF-1alpha/HO-1 pathway.
    Eur J Pharmacol. 2026;1019:178717.
    >> Share

    January 2026
  11. HUANG BB, Yu X, Cai ZD, Wu JM, et al
    CAMK1D and PI3 in Low-density Neutrophils Are Associated with the Anti-hypertensive Effects of Valsartan.
    Eur J Pharmacol. 2026 Jan 31:178613. doi: 10.1016/j.ejphar.2026.178613.
    >> Share

  12. WANG S, Song S, Feng H, Sun H, et al
    tRF-31-PS5P4PW3FJHP inhibits hypoxia-induced proliferation of pulmonary artery endothelial cells by regulating EDN1 splicing via binding to LSM4.
    Eur J Pharmacol. 2026;1011:178426.
    >> Share

    December 2025
  13. JU G, Zhang S, Zhang J, Dong F, et al
    Sodium Houttuyfonate Alleviates Monocrotaline-induced Pulmonary Hypertension by Regulating Canonical Transient Receptor Potential Channel Proteins.
    Eur J Pharmacol. 2025 Dec 25:178507. doi: 10.1016/j.ejphar.2025.178507.
    >> Share

    November 2025
  14. ZHAO X, Yin J, Lu T, Chen H, et al
    ALOX15/15B regulating autophagy to promote pulmonary arterial hypertension via PI3K/AKT/mTOR pathway.
    Eur J Pharmacol. 2025 Nov 7:178338. doi: 10.1016/j.ejphar.2025.178338.
    >> Share

  15. EIVAZI M, Hosseini K, Alipanahi S, Xia H, et al
    Deep learning-driven proteomics analysis for gene annotation in the renin-angiotensin system.
    Eur J Pharmacol. 2025;1006:178119.
    >> Share

  16. BAI Y, Jiang Y, Zhou Y, Xia Y, et al
    The Role of Ferroptosis in the Pathogenesis of Pulmonary Hypertension and Its Therapeutic Potential.
    Eur J Pharmacol. 2025 Nov 1:178316. doi: 10.1016/j.ejphar.2025.178316.
    >> Share

    September 2025
  17. QIN Y, Sha Z, Qiao Y, Yan G, et al
    Phospholysine phosphohistidine inorganic pyrophosphate phosphatase Suppresses Glycolysis and Proliferation of Pulmonary Artery Smooth Muscle Cells in Hypoxic Pulmonary Hypertension via Inhibition of lactate dehydrogenase A.
    Eur J Pharmacol. 2025 Sep 20:178172. doi: 10.1016/j.ejphar.2025.178172.
    >> Share

  18. YU X, Li Q, Zhang D, Guo K, et al
    KN060-a humanized dual-domain antibody simultaneously targeting FXI-A2/A3 epitopes: Pioneering the anti-coagulation factor XI strategy for Aterial hypertension - Evidence from preclinical models.
    Eur J Pharmacol. 2025;1006:178171.
    >> Share

  19. CHANDHRU M, Ramamurthy K, Sudhakaran G, Choi KC, et al
    Aging-related epigenetic instability in lncRNAs and miRNAs mediates the development of hypertension.
    Eur J Pharmacol. 2025 Sep 12:178150. doi: 10.1016/j.ejphar.2025.178150.
    >> Share

    July 2025
  20. LU GQ, Sun HY, Xu MY, Sun ZY, et al
    Salidroside ameliorates monocrotaline-induced pulmonary arterial hypertension in rats by modulating BKCa channels.
    Eur J Pharmacol. 2025;1004:177950.
    >> Share

  21. LI Y, Zhang Y, Chen Y, Qiao Z, et al
    SIRT3 mediates Tubeimoside I's inhibition on pulmonary artery smooth muscle cell proliferation and oxidative stress in pulmonary arterial hypertension.
    Eur J Pharmacol. 2025 Jul 18:177938. doi: 10.1016/j.ejphar.2025.177938.
    >> Share

  22. LI WH, Ma WJ, Zhang W, Zhao SN, et al
    Programmed Cell Death: A Pivotal Player in Pulmonary Arterial Hypertension.
    Eur J Pharmacol. 2025 Jul 8:177934. doi: 10.1016/j.ejphar.2025.177934.
    >> Share

  23. MA WJ, Li WH, Zhao XM, Zhang W, et al
    Significance of ALDH3A2, a mitochondrial metabolism and glycolysis related gene, in pulmonary arterial hypertension.
    Eur J Pharmacol. 2025;1003:177923.
    >> Share

  24. HOU B, Su S, Ji L, Huayu M, et al
    Luteolin alleviates right ventricular hypertrophy in high altitude pulmonary hypertension rats by regulating PI3K/AKT/mTOR signalling pathway.
    Eur J Pharmacol. 2025 Jul 1:177898. doi: 10.1016/j.ejphar.2025.177898.
    >> Share

  25. GAO C, Li J, Feng F, Fu J, et al
    EDIL3 regulates pulmonary artery smooth muscle cell proliferation and migration via integrin alphaVbeta3/ERK1/2 axis in pulmonary hypertension.
    Eur J Pharmacol. 2025 Jul 1:177901. doi: 10.1016/j.ejphar.2025.177901.
    >> Share

    May 2025
  26. LUO M, Du Y, Liu X, Zhang S, et al
    Fecal Microbiota Transplantation Alleviates Cirrhotic Portal Hypertension in Rats via Butyrate-Mediated HDAC3 Inhibition and PI3K/Akt/eNOS Signaling Regulation.
    Eur J Pharmacol. 2025 May 27:177781. doi: 10.1016/j.ejphar.2025.177781.
    >> Share

  27. WU M, Zhou Y, Guo Z, Lian D, et al
    Isoliensinine promotes vasorelaxation and inhibits constriction by regulating the calcium channel in hypertension: In vitro and in vivo approaches.
    Eur J Pharmacol. 2025 May 23:177765. doi: 10.1016/j.ejphar.2025.177765.
    >> Share

  28. WANG Y, Zhang Y, An X, Jiang Y, et al
    New LFA-1 inhibitor Orientin reduces angiotensin II-induced vascular remodeling.
    Eur J Pharmacol. 2025;995:177426.
    >> Share

  29. MINARI TP, Pisani LP
    Exploring Sodium Nitrate Supplementation in Enhancing Nitric Oxide Bioavailability and Reducing Oxidative Stress: Implications for Blood Pressure and Endothelial Dysfunction in Hypertension.
    Eur J Pharmacol. 2025 May 3:177702. doi: 10.1016/j.ejphar.2025.177702.
    >> Share

    April 2025
  30. WANG H, Peng LJ, Lu W, Li GR, et al
    Acacetin reverses hypoxic pulmonary hypertension by inhibiting hypoxia-induced proliferation of pulmonary artery smooth muscle cells via SIRT1-HMGB1 pathway.
    Eur J Pharmacol. 2025 Apr 19:177650. doi: 10.1016/j.ejphar.2025.177650.
    >> Share

    March 2025
  31. BISWAS AM, Emran T, Khan SI, Shabnam S, et al
    Transforming Growth Factor-beta-mediated attenuation of cardio-renal oxidative stress, inflammation and fibrosis by L-arginine in fludrocortisone acetate induced-hypertensive rats.
    Eur J Pharmacol. 2025 Mar 26:177559. doi: 10.1016/j.ejphar.2025.177559.
    >> Share

  32. CARVALHO KFS, de Lima JF, Silva JLM, de Almeida CR, et al
    Toll-like receptor 9 contributes to perivascular adipose tissue dysfunction in spontaneously hypertensive rats.
    Eur J Pharmacol. 2025;998:177524.
    >> Share

    February 2025
  33. HAMDY A, El-Bassossy HM, Elshazly SM, El-Sayed SS, et al
    Statins boost beneficial pleiotropic cardiovascular effects of cilostazol in angiotensin-II hypertensive rats.
    Eur J Pharmacol. 2025 Feb 27:177442. doi: 10.1016/j.ejphar.2025.177442.
    >> Share

  34. SHANAHATI D, Yang T, Fang L, Nijiati Y, et al
    18beta-Glycyrrhetinic acid improves pulmonary hypertension by regulating the vascukar non-inflammatory molecule-1/L-arginine/nitric oxide signaling pathway.
    Eur J Pharmacol. 2025 Feb 21:177382. doi: 10.1016/j.ejphar.2025.177382.
    >> Share

  35. GUO Z, Wu M, Chen L, Chen H, et al
    Neferine attenuates hypertensive cardiomyocyte apoptosis and modulates key signaling pathways: An in vivo and in vitro study.
    Eur J Pharmacol. 2025;994:177393.
    >> Share

  36. BAI J, Gao D, Mei J, Yuan H, et al
    Exonic CircGUCY1A2 Inhibits Pulmonary Artery Smooth Muscle Cells Phenotypic Switching Via Regulating O-glycosylation of COL3A1 in Pulmonary Hypertension.
    Eur J Pharmacol. 2025 Feb 4:177328. doi: 10.1016/j.ejphar.2025.177328.
    >> Share

    January 2025
  37. JOVANOVIC A
    Editorial: Research and development of new treatments for hypertension.
    Eur J Pharmacol. 2025 Jan 31:177321. doi: 10.1016/j.ejphar.2025.177321.
    >> Share

  38. JOVANOVIC A
    Editorial: Research and development of new treatments for hypertension.
    Eur J Pharmacol. 2025 Jan 28:177318. doi: 10.1016/j.ejphar.2025.177318.
    >> Share

    December 2024
  39. SHARMA A, Kapur S, Kancharla P, Yang T, et al
    Sex differences in gut microbiota, hypertension, and cardiovascular risk.
    Eur J Pharmacol. 2024;987:177183.
    >> Share

  40. GAWRYS O, Kala P, Sadowski J, Melenovsky V, et al
    Soluble guanylyl cyclase stimulators and activators: Promising drugs for the treatment of hypertension?
    Eur J Pharmacol. 2024;987:177175.
    >> Share

    November 2024
  41. LU G, Du R, Lu L, Wang Q, et al
    Macrophage-specific kappa-OR knockout exacerbates inflammation in hypoxic pulmonary hypertension.
    Eur J Pharmacol. 2024 Nov 23:177152. doi: 10.1016/j.ejphar.2024.177152.
    >> Share

  42. PARVAN R, Aboumsallem JP, Meijers WC, De Boer RA, et al
    Innovative hypertension treatments: Transitioning from conventional therapies to siRNA-based solutions.
    Eur J Pharmacol. 2024;985:177110.
    >> Share

  43. ZHANG F, Guo Z, Wu M, Lin G, et al
    Trifolin Attenuates Hypertension-Mediated Cardiac Injury by Inhibiting Cardiomyocyte Apoptosis: Mechanistic Insights and Therapeutic Potential.
    Eur J Pharmacol. 2024 Nov 9:177125. doi: 10.1016/j.ejphar.2024.177125.
    >> Share

  44. BROSOLO G, Da Porto A, Marcante S, Capilupi F, et al
    The role for omega-3 polyunsaturated and short chain fatty acids in hypertension: An updated view on the interaction with gut microbiota.
    Eur J Pharmacol. 2024;985:177107.
    >> Share

  45. LIU A, Wang Y, Zheng S, Bao Z, et al
    Endonuclear Circ-calm4 regulates ferroptosis via a circR-Loop of the COMP gene in pulmonary artery smooth muscle cells.
    Eur J Pharmacol. 2024;982:176944.
    >> Share

    October 2024
  46. LIU DD, Liu XL, Zheng TF, Li X, et al
    Dapagliflozin alleviates right heart failure by promoting collagen degradation by reducing ROS levels.
    Eur J Pharmacol. 2024;981:176875.
    >> Share

  47. WINNER G J, Jain S, Gupta D
    Unveiling Novel Molecules and Therapeutic Targets in Hypertension - A Narrative Review.
    Eur J Pharmacol. 2024 Oct 9:177053. doi: 10.1016/j.ejphar.2024.177053.
    >> Share

  48. WANG H, Gao Y, Bai J, Liu H, et al
    CircLMBR1 inhibits phenotypic transformation of hypoxia-induced pulmonary artery smooth muscle via the splicing factor PUF60.
    Eur J Pharmacol. 2024;980:176855.
    >> Share

    September 2024
  49. R MURALITHARAN R, Marques FZ, O'Donnell JA
    Recent advancements in targeting the immune system to treat hypertension.
    Eur J Pharmacol. 2024 Sep 18:177008. doi: 10.1016/j.ejphar.2024.177008.
    >> Share

  50. CASTIGLIONI L, Gelosa P, Muluhie M, Mercuriali B, et al
    Fenofibrate reduces cardiac remodeling by mitochondrial dynamics preservation in a renovascular model of cardiac hypertrophy.
    Eur J Pharmacol. 2024;978:176767.
    >> Share

  51. BLASCKE DE MELLO MM, Neves VGO, Parente JM, Pernomian L, et al
    Sarcoplasmic reticulum calcium ATPase (SERCA) proteolysis by matrix metalloproteinase-2 contributes to vascular dysfunction in early hypertension.
    Eur J Pharmacol. 2024;983:176981.
    >> Share

    July 2024
  52. WANG Y, Han D, Chai L, Qiu Y, et al
    MFN2-dependent mitochondrial dysfunction contributes to Relm-beta-induced pulmonary arterial hypertension via USP18/Twist1/miR-214 pathway.
    Eur J Pharmacol. 2024 Jul 31:176828. doi: 10.1016/j.ejphar.2024.176828.
    >> Share

  53. ZHAO Z, Fan Q, Zhang C, Zheng L, et al
    Imperatorin attenuates CCl(4)-induced cirrhosis and portal hypertension by improving vascular remodeling and profibrogenic pathways.
    Eur J Pharmacol. 2024 Jul 30:176833. doi: 10.1016/j.ejphar.2024.176833.
    >> Share

  54. BLAZEK O, Bakris GL
    A review of Novel Endothelin antagonists and overview of non-steroidal mineralocorticoid antagonists for treating resistant hypertension: An Update.
    Eur J Pharmacol. 2024 Jul 22:176752. doi: 10.1016/j.ejphar.2024.176752.
    >> Share

    June 2024
  55. WANG X, Cui L, Wang Y, Zeng Z, et al
    Mechanistic investigation of wogonin in delaying the progression of endothelial mesenchymal transition by targeting the TGF-beta1 pathway in pulmonary hypertension.
    Eur J Pharmacol. 2024;978:176786.
    >> Share

  56. DAI X, Liu Y, Wu Y, Wang S, et al
    DYZY01 alleviates pulmonary hypertension via inhibiting endothelial cell pyroptosis and rescuing endothelial dysfunction.
    Eur J Pharmacol. 2024;978:176785.
    >> Share

    May 2024
  57. SHELKE V, Dagar N, Puri B, Gaikwad AB, et al
    Natriuretic peptide system in hypertension: Current understandings of its regulation, targeted therapies and future challenges.
    Eur J Pharmacol. 2024;976:176664.
    >> Share

    April 2024
  58. YAMAMURA A, Fujiwara M, Kawade A, Amano T, et al
    Corosolic acid attenuates platelet-derived growth factor signaling in macrophages and smooth muscle cells of pulmonary arterial hypertension.
    Eur J Pharmacol. 2024;973:176564.
    >> Share

  59. LAXMI, Golmei P, Srivastava S, Kumar S, et al
    Single nucleotide polymorphism-based biomarker in primary hypertension.
    Eur J Pharmacol. 2024;972:176584.
    >> Share

  60. LI Q, Cao H, Xu X, Chen Y, et al
    Resveratrol attenuates cyclosporin A-induced upregulation of the thromboxane A(2) receptor and hypertension via the AMPK/SIRT1 and MAPK/NF-kappaB pathways in the rat mesenteric artery.
    Eur J Pharmacol. 2024;972:176543.
    >> Share

    March 2024
  61. BENCZE M, Boros A, Behuliak M, Vavrinova A, et al
    Changes in cardiovascular autonomic control induced by chronic inhibition of acetylcholinesterase during pyridostigmine or donepezil treatment of spontaneously hypertensive rats.
    Eur J Pharmacol. 2024 Mar 25:176526. doi: 10.1016/j.ejphar.2024.176526.
    >> Share

  62. WANG J, Liu C, Huang SS, Wang HF, et al
    Functions and novel regulatory mechanisms of key glycolytic enzymes in pulmonary arterial hypertension.
    Eur J Pharmacol. 2024;970:176492.
    >> Share

  63. CHEN Y, Liu J, Zhang Q, Chai L, et al
    Activation of CaMKII/HDAC4 by SDF1 contributes to pulmonary arterial hypertension via stabilization Runx2.
    Eur J Pharmacol. 2024;970:176483.
    >> Share

  64. TANNA S, Doshi G, Godad A
    siRNA as potential therapeutic strategy for hypertension.
    Eur J Pharmacol. 2024;969:176467.
    >> Share

    February 2024
  65. FU LY, Yang Y, Tian H, Jia XY, et al
    Central administration of AICAR attenuates hypertension via AMPK/Nrf2 pathway in the hypothalamic paraventricular nucleus of hypertensive rats.
    Eur J Pharmacol. 2024 Feb 8:176373. doi: 10.1016/j.ejphar.2024.176373.
    >> Share

    January 2024
  66. LIU Q, Luo Q, Zhong B, Tang K, et al
    Salidroside attenuates myocardial remodeling in DOCA-salt-induced mice by inhibiting the endothelin 1 and PI3K/AKT/NFkappaB signaling pathways.
    Eur J Pharmacol. 2024;962:176236.
    >> Share

  67. LI MH, Liu X, Xie YL, Tang XG, et al
    Sodium butyrate alleviates right ventricular hypertrophy in pulmonary arterial hypertension by inhibiting H19 and affecting the activation of let-7g-5p/IGF1 receptor/ERK.
    Eur J Pharmacol. 2024 Jan 2:176315. doi: 10.1016/j.ejphar.2024.176315.
    >> Share

    December 2023
  68. FAN Q, Wu G, Chen M, Luo G, et al
    Cediranib ameliorates portal hypertensive syndrome via inhibition of VEGFR-2 signaling in cirrhotic rats.
    Eur J Pharmacol. 2023 Dec 27:176278. doi: 10.1016/j.ejphar.2023.176278.
    >> Share

  69. QAYYUM MI, Ullah S, Rashid U, Sadiq A, et al
    N-phenyl and N-benzyl substituted succinimides: Preclinical evaluation for their antihypertensive effect and underlying mechanism.
    Eur J Pharmacol. 2023 Dec 22:176195. doi: 10.1016/j.ejphar.2023.176195.
    >> Share

  70. HUANG J, Xie Y, Chen B, Xia Y, et al
    GPR146 regulates pulmonary vascular remodeling by promoting pulmonary artery smooth muscle cell proliferation through 5-lipoxygenase.
    Eur J Pharmacol. 2023;961:176123.
    >> Share

  71. LI D, Chen Y, Wang Y, Liu J, et al
    NAMPT mediates PDGF-induced pulmonary arterial smooth muscle cell proliferation by TLR4/NF-kappaB/PLK4 signaling pathway.
    Eur J Pharmacol. 2023;961:176151.
    >> Share

  72. SILVA-VELASCO DL, Hong E, Beltran-Ornelas JH, Sanchez-Lopez A, et al
    Hydrogen sulfide ameliorates hypertension and vascular dysfunction induced by insulin resistance in rats by reducing oxidative stress and activating eNOS.
    Eur J Pharmacol. 2023 Dec 12:176266. doi: 10.1016/j.ejphar.2023.176266.
    >> Share

  73. MANEESAI P, Potue P, Khamseekaew J, Sangartit W, et al
    Kaempferol protects against cardiovascular abnormalities induced by nitric oxide deficiency in rats by suppressing the TNF-alpha pathway.
    Eur J Pharmacol. 2023;960:176112.
    >> Share

  74. XU Q, Zhuo K, Zhang X, Zhen Y, et al
    The role of angiotensin II activation of yes-associated protein/PDZ-binding motif signaling in hypertensive cardiac and vascular remodeling.
    Eur J Pharmacol. 2023 Dec 5:176252. doi: 10.1016/j.ejphar.2023.176252.
    >> Share

    November 2023
  75. VAN DORST DCH, Mirabito Colafella KM, van Veghel R, Garrelds IM, et al
    Cyclooxygenase-2 inhibition prevents renal toxicity but not hypertension during sunitinib treatment.
    Eur J Pharmacol. 2023 Nov 27:176199. doi: 10.1016/j.ejphar.2023.176199.
    >> Share

  76. HO CY, Sun GC, Lin YT, Wong TY, et al
    Microglial activation and toll-like receptor 4-Dependent regulation of angiotensin II type I receptor-mu-opioid receptor 1 heterodimerization and hypertension in fructose-fed rats.
    Eur J Pharmacol. 2023 Nov 21:176171. doi: 10.1016/j.ejphar.2023.176171.
    >> Share

  77. MATSUMOTO T, Taguchi K, Kobayashi T
    Role of TRPV4 on vascular tone regulation in pathophysiological states.
    Eur J Pharmacol. 2023;959:176104.
    >> Share

  78. EDOSUYI O, Igbe I, Oyekan A
    Fumarate and its downstream signalling pathways in the cardiorenal system: Recent insights and novel expositions in the etiology of hypertension.
    Eur J Pharmacol. 2023 Nov 7:176186. doi: 10.1016/j.ejphar.2023.176186.
    >> Share

  79. YI Y, Tianxin Y, Zhangchi L, Cui Z, et al
    Pinocembrin attenuates susceptibility to atrial fibrillation in rats with pulmonary arterial hypertension.
    Eur J Pharmacol. 2023;960:176169.
    >> Share

    October 2023
  80. KONG S, Yu J, Li HF, Xie YL, et al
    A ring N(CH(3))(2)-based derivative of resveratrol inhibits pulmonary vascular remodeling in hypoxia pulmonary hypertension.
    Eur J Pharmacol. 2023 Oct 9:176077. doi: 10.1016/j.ejphar.2023.176077.
    >> Share

    September 2023
  81. NOAH AA, El-Mezayen NS, El-Ganainy SO, Darwish IE, et al
    Reversal of fibrosis and portal hypertension by Empagliflozin treatment of CCl(4)-induced liver fibrosis: Emphasis on gal-1/NRP-1/TGF-beta and gal-1/NRP-1/VEGFR2 pathways.
    Eur J Pharmacol. 2023 Sep 26:176066. doi: 10.1016/j.ejphar.2023.176066.
    >> Share

  82. VALOVIC P, Behuliak M, Vaneckova I, Zicha J, et al
    Impaired vascular beta-adrenergic relaxation in spontaneously hypertensive rats: The differences between conduit and resistance arteries.
    Eur J Pharmacol. 2023 Sep 12:176045. doi: 10.1016/j.ejphar.2023.176045.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016